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Abstract
The investigation of the antifungal activities of drugs whose primary activities are not
related to their antimicrobial potential is in the current forefront of research. Statin com-
pounds, which are routinely used as cholesterol-lowering drugs, may also exert direct an-
timicrobial effects. In this study, the in vitro antifungal activities of various statins (lovas-
tatin, simvastatin, fluvastatin, atorvastatin, rosuvastatin and pravastatin) were examined
against one isolate each of four dermatophyte species (Trichophyton mentagrophytes,
Trichophyton rubrum, Microsporum canis andMicrosporum gypseum). Basically, statins
were effective in inhibiting all dermatophyte studied, but were particularly active against
M. canis and T. mentagrophytes. Fluvastatin and simvastatin were active against all of
the tested fungi causing a complete inhibition of their growth at very low concentrations
(6.25–12.5μg/ml). Lovastatin and rosuvastatin had inhibitory effects at higher concen-
trations (25–128μg/ml), while atorvastatin and pravastatin proved the less effective. The
in vitro interactions between statins and different antifungals (ketoconazole, itraconazole,
fluconazole, amphotericin B, nystatin, griseofulvin, terbinafine and primycin) were also
investigated using a standard chequerboard broth microdilution method. Synergetic in-
teractions were observed in several cases, most of them were noticed when statins were
combined with terbinafine and the different azoles. Some combinations were particularly
active (ketoconazole-simvastatin or terbinafine-simvastatin), as they were found to exert
synergistic effect against all of the investigated isolates. The other antifungals showed
synergistic interactions with statins in only certain cases. These results suggest that
statins exert substantial antifungal effects against dermatophyte fungi and they should
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be promising components in a combination therapy as they can act synergistically with
a number of clinically used antifungal agents.
Key words: Statin, dermatophytes, antifungal susceptibility testing, drug combination, synergism.
Introduction
More and more studies have focused on the antifungal ac-
tivities of drugs not routinely used in the treatment of fun-
gal diseases, as well as on the development of antifungal
combination therapies with such compounds [1]. Statins
are the most frequently applied cholesterol-lowering drugs
as they inhibit 3-hydroxy-3-methylglutaryl-coenzyme A re-
ductase, the enzyme that catalyzes the conversion of 3-
hydroxy-3-methylglutaryl-coenzyme A to mevalonic acid,
the rate-limiting step of the sterol biosynthetic pathway
[2]. Besides hyperlipidemia control, statins have several
cholesterol-independent (pleiotropic) effects as well, e.g.,
they improve the endothelial function by stimulating the
production of nitrogen monoxide of endothelial cells, in-
hibit the aggregation of platelets, reduce the accumulation
of β-amyloid in brain inhibiting the development of de-
mentia [2]. They have antioxidant and anti-inflammatory
effects as well, since these agents modify the inflammatory
cascades by pleiotropic actions at multiple levels [3].
There is increasing evidence for the potential use of
statins in preventing and treating infections as they at-
tenuate the virulence and pathogenicity of microorgan-
isms and modulate signaling and other regulatory path-
ways involved in controlling infection [4–6]. Statins exert
substantial growth-inhibitory effects on the growth of dif-
ferent pathogenic fungi in that recent studies have revealed
their direct antimicrobial effect against yeasts, as well as
ascomycetous and zygomycetous molds [7–10]. There are
also sporadic new reports on the combined application of
statins and different antimycotics against fungi [11–19].
However, no data have been found about the antifungal
effects of statins on the growth of dermatophyte fungi. Der-
matophytes are a group of closely related fungi that have a
high affinity to keratinized tissues such as skin, hair, body
hair and nails, which are members of three genera, i.e., Epi-
dermophyton, Microsporum and Trichophyton. Based on
their natural habitats, three groups can be differentiated,
i.e., geophilic (found primarily in soil) saprophytic species
(M. gypseum, T. ajelloi), zoophilic species (routinely en-
countered on animals; M. canis, T. verrucosum) and an-
thropophilic species (naturally associated with humans; T.
rubrum, E. floccosum, M. audounii, T. tonsurans) [20].
These fungi can attack the human and animal keratinized
tissues and cause a wide spectrum of clinical manifesta-
tions of superficial infections. Dermatophytosis is one of
the most common fungal infections worldwide and the in-
cidence of infections has been increasing, particularly in im-
munocompromised patients [21]. Dermatophyte infections
generally need prolonged treatment with topical and sys-
temic antifungal agents. Although, localized non-extensive
lesions respond well to topical antifungal therapy, other ex-
tensive infections, particularly involving the scalp or nails,
require prolonged systemic therapy [22]. Oral treatment
with antifungal agents such as terbinafine, itraconazole,
ketoconazole and fluconazole constitutes the treatment of
choice for dermatophytoses that fail to respond to topical
therapy [23,24].
The aim of the present work was to investigate the
in vitro antifungal activities of the most important, com-
mercially available statins – lovastatin (LOV), pravastatin
(PRA), simvastatin (SIM), fluvastatin (FLV), atorvastatin
(ATO) and rosuvastatin (ROS) alone and also in combi-
nation with the most widely used antifungal compounds –
ketoconazole (KTC), itraconazole (ITC), fluconazole (FLC),
amphotericin B (AMB), nystatin (NYT), griseofulvin (GRS),
terbinafine (TRB) and primycin (PN) against different
dermatophyte fungi.
Materials and methods
Strains and media
The following fungal strains were used in this study;
Trichophyton rubrum (American Type Culture Collec-
tion, USA; ATCC 28188), Trichophyton mentagrophytes
(ATCC 9533), Microsporum gypseum (ATCC 24102) and
Microsporum canis (ATCC 36299) and Candida albicans
(ATCC 90028) as the reference strain in the antifungal sus-
ceptibility tests. The isolates were maintained on potato
dextrose agar slants (PDA, Difco, 0.4% potato starch, 2%
glucose, 1.5% agar) at 4◦C.
Antifungal agents
The statins used in this study were: fluvastatin (Lescol;
Novartis), lovastatin (Mevacor; Merck Sharp & Dohme),
simvastatin (Vasilip; Egis), rosuvastatin (Crestor; As-
traZeneca) and atorvastatin (Atorvox; Richter), which were
all pharmaceutical grade and pravastatin (Sigma-Aldrich),
which was provided as standard powder. The azoles
used were ketoconazole, fluconazole and itraconazole, pro-
vided by the manufacturer (Sigma-Aldrich) as standard
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powders as were nystatin (Sigma-Aldrich), griseoful-
vin (Sigma-Aldrich), terbinafine (LGC Promochem) and
primycin (PannonPharma, Pe´csva´rad, Hungary). In con-
trast, amphotericin B (Sigma-Aldrich) was purchased as a
stock solution (250μg/ml in deionized water).
Fresh stock solutions of the statins were prepared in
methanol, with the exception of pravastatin, which was dis-
solved in distilled water. Lovastatin and simvastatin were
activated from their lactone pro-drug forms by hydrolysis in
ethanolic NaOH [15% (v/v) ethanol, 0.25% (w/v) NaOH]
at 60◦C for 1 h as described by Lorenz and Parks right be-
fore the antifungal assays [25]. Stock solutions of primycin,
nystatin, ketoconazole, itraconazole and terbinafine were
made in dimethyl sulfoxide (Sigma-Aldrich), while flu-
conazole and griseofulvin were dissolved in dimethylfor-
mamide (Reanal). Stock solutions were stored at −80◦C
until needed.
Antifungal susceptibility testing
The in vitro antifungal activities of the various statins and
antimycotics were determined against dermatophyte fungi
using a broth microdilution method, which was performed
according to the guideline M38-A2 proposed by the Clin-
ical and Laboratory Standards Institute (CLSI) with some
modifications [26]. TheC. albicansATCC90028 strain was
involved as a reference strain, its antifungal susceptibility
testing was performed according to the M27-A3 guideline
[27].
Theminimal inhibitory concentration (MIC) values were
determined in 96-well flat-bottomed microtiter plates by
measuring the optical density (OD) of the fungal growth in
culture at 620 nm, in a test medium of RPMI 1640 (Sigma-
Aldrich) containing L-glutamine, but lacking sodium bicar-
bonate, buffered to pH 7.0with 0.165M3-(N-morpholino)
propanesulfonic acid (Sigma-Aldrich). Inocula of dermato-
phyte fungi were prepared using the modified method of
Santos et al. [28] which first consisted of growing the strains
on PDA slants at 30◦C for 14 days. The fungal colonies were
then covered with 5 ml RPMI 1640 medium and suspen-
sions prepared by scraping the agar surface with the tip
of a pipette to generate a suspension containing a mixture
of conidia and hyphal elements. This mixture was trans-
ferred to a sterile tube and let stand for 15–20 min at room
temperature to allow the heavy particles to settle out. The
upper fraction was then filtered through a membrane (pore
size 8μm, Sartorius), which retained hyphal elements but
allowed for the passage of dermatophyte microconidia. The
concentration of microconidia in the suspensions was de-
termined through the use of a haemocytometer and then
they were diluted in RPMI 1640 to prepare a final inocu-
lum suspension containing 103–104 CFU/ml microconidia.
Inoculum quantification was accomplished by inoculating
10μl of each type of inoculum suspension onto PDA agar,
then incubating the plates at 30◦C to count the colonies as
they became visible to determine the CFU/ml.
The statins and the antifungal agents were tested in se-
ries of two-fold dilutions at concentrations ranging from:
0.25–128μg/ml for statins; 0.125–64μg/ml for fluconazole,
primycin and griseofulvin; 0.031–16μg/ml for ketocona-
zole, nystatin and amphotericin B; and 0.016–8μg/ml for
itraconazole and terbinafine. The microtiter plates were in-
cubated for 4 days at 30◦C, and the endpoint determination
was done by visually and spectrophotometrically to quan-
tify the growth of the fungal cultures. The OD was mea-
sured at 620 nm with a microtiter plate reader (Jupiter HD;
ASYS Hitech). Uninoculated medium was used as the back-
ground for the spectrophotometric calibration; the growth
control wells contained inoculum suspension in the drug-
free medium. The solvent control wells contained inocu-
lum suspension in the drug-free solvent-containing (1%)
medium to demonstrate that the solvent had no inhibitory
effect on the investigated fungi at the concentration investi-
gated. For calculation of the extent of inhibition, the OD620
readings of the drug-free control cultures were set at 100%
growth. The MICs for the statins and the antifungals were
determined as the lowest concentration of drugs that pro-
duced an optically clear well after four days incubation. The
quality-control strain was included on each occasion that
an isolate was tested and all experiments were performed
in duplicate.
Chequerboard broth microdilution method
For drug interaction studies, each statin was tested with
each antifungal compound by the chequerboard broth mi-
crodilution method. The statins and the antifungal agents
were tested at series of two-fold dilutions at concentrations
ranging from 0.391–25μg/ml for statins and from 0.004–
2μg/ml for terbinafine. The concentrations of other anti-
fungals, the inoculum preparation, the initial inoculum, the
controls and the conditions of the incubation were the same
as described above for antifungal susceptibility testing.
Data analysis
A calculation matrix was created to convert OD620 read-
ings into measurements of growth as percentages of control
readings. In the chequerboard broth microdilution method,
the interaction ratio (IR) between the antifungal agents was
calculated using the Abbott formula: IR = Io / Ie, where Io
is the observed percentage inhibition and Ie is the expected
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percentage inhibition for a given interaction. Ie was calcu-
lated using the formula: Ie = X + Y – (XY/100), where
X and Y are the percentage inhibitions observed for each
compound when applied alone. The IR reflects the nature
of the interaction between the antifungal compounds: an
IR > 1.5 denotes synergism and an IR < 0.5 denotes an-
tagonism [29]. If IR is between 0.5 and 1.5, the interaction
is considered additive by Gisi [29]; however, we designated
these interactions as indifferent since additivism is not a
valid category. The interaction ratio between the antifungal
agents was also calculated by using the fractional inhibitory
concentration index (FICI), according to the equation
A/MICA + B/MICB = FICA + FICB = FIC index, where
A and B are the MICs of drug A and drug B in the combi-
nation, MICA andMICB are theMICs of drug A and drug B
alone, and FICA and FICB are the FICs of drug A and drug
B. FIC indexes were interpreted as follows: ≤0.5, synergy;
>0.5 to <4.0, indifference; and ≥4.0, antagonism [30,31].
Results
In vitro susceptibility testing
The in vitro antifungal activities of lovastatin, simvastatin,
fluvastatin, rosuvastatin, atorvastatin and pravastatin were
determined against the four indicated dermatophytes strains
in the range of 0.25–128μg/ml by the broth microdilu-
tion method. The MICs of the statins were regarded as
the lowest concentration of drugs that produced greater
than 90% growth inhibition, but it should be noted that
50% growth-inhibitory concentrations (IC50) were also de-
termined. Since we had established the MIC values of the
investigated statins against C. albicans ATCC 90028 in a
previous study we used it as a control in these tests [16]. The
MICs of the different statins against dermatophyte strains
are reported in Table 1.
Dermatophyte fungi were sensitive to the statins and
the different species showed similar patterns of suscepti-
bility to each statin tested. However, the antifungal effects
of the different statins varied what with fluvastatin and
simvastatin displaying the strongest antifungal activity, fol-
lowed in sequence by lovastatin, rosuvastatin, atorvastatin
and pravastatin. The natural statins (lovastatin and sim-
vastatin) were inactive in the form of the pro-drugs, but
their active metabolites (obtained by hydrolysis of the lac-
tone ring at pH 10) manifested pronounced antifungal ef-
fects. Fluvastatin and simvastatin were active against all of
the tested fungi completely inhibiting their growth at very
low concentrations (6.25–12.5μg/ml). Lovastatin and ro-
suvastatin had inhibitory effects at higher concentrations
(25–128μg/ml), atorvastatin inhibited the growth of only
Table 1.MICs of the investigated statins against dermatophyte
strains.
MIC values (µg/ml)
Strain Statin IC50 MIC
Trichophyton rubrum
(ATCC 28188)
LOV 16–25 25–32
SIM 3.125 6.25–12.5
FLV 1.56–3.125 6.25
ROS 64 128
ATO 64–128 >128
PRA >128 >128
Trichophyton mentagrophytes
(ATCC 9533)
LOV 12.5–25 25–32
SIM 1.56–3.125 6.25
FLV 3.125 6.25–12.5
ROS 32 64
ATO 32 64–128
PRA 128 >128
Microsporum gypseum
(ATCC 24102)
LOV 25–32 32–64
SIM 3.125–6.25 6.25–12.5
FLV 3.125–6.25 8
ROS 128 >128
ATO 128 >128
PRA >128 >128
Microsporum canis
(ATCC 36299)
LOV 12.5–25 32
SIM 1.56 6.25–12.5
FLV 1.56 6.25–12.5
ROS 16–32 64
ATO 32 128
PRA 64 >128
IC50, 50% growth-inhibitory concentration; MIC, minimal inhibitory concen-
tration; LOV, lovastatin; SIM, simvastatin; FLV, fluvastatin; ROS, rosuvas-
tatin; ATO, atorvastatin; PRA, pravastatin.
T. mentagrophytes andM. canis at the highest applied con-
centration, whilst pravastatin proved completely ineffective
against all isolates at the concentrations used in these stud-
ies. Fungi were equally sensitive to the statins, although
M. canis and T. mentagrophytes proved to be the most sen-
sitive strains. Trichophyton rubrum and M. gypseum were
also sensitive to statins, but their MIC values were higher
with one or two dilutions.
The in vitro MICs of the investigated antifungal agents
were also determined (Table 2), which were regarded,
mainly for the azoles, as the lowest concentrations that
produced prominent inhibition of growth (approximately
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Table 2. The statin-antifungal agent combinations displaying synergistic interactions against the investigated dermatophytes
strains.
Statin
[MIC alone Antifungal agent MIC in combination
Strain (µg/ml)]a [MIC alone (µg/ml)]b (µg/ml)c IR Id FICI Ie
Trichophyton rubrum
ATCC 28188 LOV [25–32] FLC [1–2] 12.5 + 0.25 1.50 S 0.64 I
TRB [0.016–0.03] 6.25 + 0.008 0.94 I 0.50 S
SIM [6.25–12.5] KTC [0.06–0.5] 0.39 + 0.06 0.86 I 0.09 S
3.125 + 0.03 0.86 I 0.28 S
ITC [0.06–0.25] 0.39 + 0.06 0.88 I 0.28 S
3.125 + 0.03 1.11 I 0.38 S
FLC [1–2] 3.125 + 0.5 1.75 S 0.50 S
TRB [0.016–0.03] 0.78 + 0.008 0.86 I 0.38 S
PN [16–32] 3.125 + 2 1.18 I 0.31 S
FLV [6.25] KTC [0.06–0.5] 0.39 + 0.03 0.83 I 0.31 S
FLC [1–2] 1.56 + 0.25 1.64 S 0.50 S
TRB [0.016–0.03] 1.56 + 0.008 0.89 I 0.50 S
ROS [128] KTC [0.06–0.5] 0.39 + 0.03 0.69 I 0.504 S
FLC [1–2] 0.39 + 2 0.91 I 0.504 S
6.25 + 1 0.93 I 0.30 S
25 + 0.5 2.70 S 0.32 S
TRB [0.016–0.03] 25 + 0.004 1.03 I 0.45 S
ATO [>128] KTC [0.06–0.5] 0.39 + 0.06 0.87 I <0.502f S
0.78 + 0.03 0.96 I <0.25f S
ITC [0.06–0.25] 0.39 + 0.03 1.22 I <0.25f S
6.25 + 0.016 2.28 S <0.15f S
FLC [1–2] 0.39 + 1 0.94 I <0.502f S
12.5 + 0.5 1.32 I <0.30f S
TRB [0.016–0.03] 0.39 + 0.008 0.69 I <0.501f S
12.5 + 0.004 0.80 I <0.30f S
PRA [>128] AMB [2] 0.39 + 1 0.78 I <0.504f S
Trichophyton mentagrophytes
ATCC 9533 LOV [25–32] TRB [0.016] 3.125 + 0.008 1.05 I 0.38 S
SIM [6.25] KTC [0.5–1] 1.56 + 0.03 1.15 I 0.31 S
FLC [>64] 1.56 + 32 1.00 I <0.5f S
TRB [0.016] 0.78 + 0.004 0.99 I 0.50 S
FLV [6.25–12.5] KTC [0.5–1] 3.125 + 0.125 1.49 I 0.38 S
ATO [64–128] TRB [0.016] 25 + 0.004 1.48 I 0.45 < x < 0.64f S/I
Microsporum gypseum
ATCC 24102 LOV [32–64] KTC [1–2] 25 + 0.5 1.69 S 0.64 I
FLC [> 64] 12.5 + 1 1.08 I <0.21f S
25 + 0.125 0.66 I <0.39f S
TRB [0.06–0.125] 6.25 + 0.03 1.42 I 0.50 S
SIM [6.25–12.5] AMB [2–4] 0.78 + 2 1.61 S 0.56 I
NYT [4–8] 1.56 + 4 1.53 S 0.63 I
KTC [1–2] 3.125 + 0.06 2.28 S 0.56 I
ITC [0.06–0.125] 3.125 + 0.016 1.27 I 0.38 S
FLC [> 64] 0.78 + 32 2.60 S <0.38f S
1.56 + 16 1.96 S <0.38f S
3.125 + 0.5 1.53 S <0.504f S
TRB [0.06–0.125] 3.125 + 0.016 1.37 I 0.50 S
GRS [0.5–1] 3.125 + 0.125 0.88 I 0.50 S
FLV [8] KTC [1–2] 1.56 + 0.125 1.74 S 0.38 S
FLC [> 64] 3.125 + 32 3.39 S <0.50f S
6.25 + 0.125 1.09 I <0.50f S
TRB [0.06–0.125] 3.125 + 0.03 0.94 I 0.50 S
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Table 2 (Continued)
Statin
[MIC alone Antifungal agent MIC in combination
Strain (µg/ml)]a [MIC alone (µg/ml)]b (µg/ml)c IR Id FICI Ie
GRS [0.5–1] 3.125 + 0.25 1.87 S 0.50 S
ROS [>128] NYT [4–8] 25 + 2 2.09 S <0.70f I
KTC [1–2] 25 + 0.25 2.70 S <0.70f I
ITC [0.06–0.125] 25 + 0.03 1.73 S <0.70f I
ATO [>128] KTC [1–2] 0.78 + 1 0.98 I <0.503f S
25 + 0.5 2.04 S <0.35f S
ITC [0.06–0.125] 0.39 + 0.06 1.00 I <0.502f S
0.78 + 0.03 1.37 I <0.25f S
12.5 + 0.016 1.81 S <0.17f S
FLC [> 64] 3.125 + 64 1.90 S <0.51f I
6.25 + 32 2.97 S <0.27f S
12.5 + 16 1.57 S <0.17f S
25 + 4 1.37 I <0.13f S
TRB [0.06–0.125] 25 + 0.016 1.55 S <0.35f S
Microsporum canis
ATCC 36299 SIM [6.25–12.5] AMB [1–2] 0.78 + 1 2.71 S 0.63 I
NYT [4–8] 0.39 + 0.5 1.09 I 0.19 S
0.78 + 0.25 0.70 I 0.19 S
1.56 + 0.125 0.76 I 0.28 S
KTC [0.25–1] 0.39 + 0.03 0.82 I 0.28 S
TRB [0.03–0.06] 1.56 + 0.016 0.77 I 0.31 S
6.25 + 0.008 0.69 I 0.38 S
PRA [>128] ITC [0.016–0.125] 25 + 0.06 0.85 I <0.45f S
MIC, minimal inhibitory concentration; IR, interaction ratio; FICI, fractional inhibitory concentration index; LOV, lovastatin; SIM, simvastatin; FLV, fluvastatin;
ROS, rosuvastatin; ATO, atorvastatin; PRA, pravastatin; AMB, amphotericin B; NYT, nystatin; KTC, ketoconazole; ITC, itraconazole; FLC, fluconazole; TRB,
terbinafine; GRS, griseofulvin; PN, primycin.
a,bThe MICs of the statins and the antifungals are shown in brackets. cThe effective concentrations of the combined drugs causing total growth inhibition are
presented; the first number indicates the concentration of the given statin, and the second number indicates the concentration of the given antifungal agent. dThe
type of the interaction (I, indifferent; S, synergistic) as inferred from the interaction ratio (IR) values calculated with the Abbott formula are presented. eThe type of
the interaction (I, indifferent; S, synergistic) as inferred from fractional inhibitory concentration index (FICI) are presented. fFICI could not be precisely calculated,
when the MIC of the given statin or the given antifungal agent could not be determined, but FICI was presumed in the calculated range.
80% inhibition). However, in Table 2 the lowest concen-
trations of drugs that produced total (above 90%) growth
inhibition were presented to make it easier to compare the
MIC values of the drug combinations.
Among the antifungals, terbinafine and itraconazole
had the strongest inhibitory effect completely blocking the
growth of all tested isolates at low concentration (0.016–
0.125μg/ml). Griseofulvin and ketoconazole were also ac-
tive at low concentrations in that their MIC values ranged
from 0.125–1.0μg/ml and from 0.06–2μg/ml, respectively.
Amphotericin B, nystatin and primycin were less effective as
growth inhibition was only observed at higher concentra-
tions (1–4μg/ml, 4–8μg/ml and 16–32μg/ml, respectively).
Fluconazole did not equally inhibit the development of the
investigated strains as the growth ofT. rubrum andM. canis
was inhibited at low concentration (1–2μg/ml and 0.125–
0.5μg/ml, respectively), but the antifungal had no effect on
the other two isolates at the administered concentrations.
Interactions between statins and antifungals
The in vitro interactions between the statins and the anti-
fungals against dermatophyte fungi were also studied using
a standard chequerboard broth microdilution method. We
investigated the inhibition of fungal growth through the use
of pairs of drugs, in order to find effective drug combina-
tions. All investigated statins were tested in combination
with all investigated antifungal compounds, and positive
interactions were observed in most situations. The data for
those drug combinations, which resulted synergistic inter-
actions are presented in Table 2. The interaction ratio (IR)
between the statins and the antifungal agents was calcu-
lated using the Abbott formula, as well as the fractional
inhibitory concentration index (FICI) [29,30]. In Table 2
IR values calculated with both methods and the types of
the interactions (according to the calculated IR) are also
given, since the IR values calculated with the two methods
reflects different interactions in some cases.
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Synergistic interactions were observed in several cases,
most of them occurring when statins were combined with
terbinafine and the different azoles. Ketoconazole and
fluconazole combined with most of the statins showed
synergistic activity against T. rubrum and M. gypseum,
and the concentrations needed to total growth-inhibition
could be decreased by several dilutions. The ketoconazole-
simvastatin combination was stronger than other com-
binations since it was synergistic against all of the in-
vestigated isolates. In contrast, the combination of keto-
conazole and fluconazole with other statins had no ef-
fect against T. mentagrophytes and M. canis. Terbinafine
also acted synergistically with statins against T. menta-
grophytes besides T. rubrum and M. gypseum. Maxi-
mum inhibition was achieved with terbinafine-simvastatin
combination since it exerted synergistic effect against
all found dermatophytes. Itraconazole-simvastatin and
itraconazole-atorvastatin acted synergistically against only
T. rubrum and M. gypseum. While itraconazole-
rosuvastatin combination was synergistic against M. gyp-
seum, itraconazole-pravastatin had a synergistic in vitro
antifungal effect against M. canis. Interactions between
statins and the other antifungals were noted only in some
cases. Amphotericin B-simvastatin combination was syn-
ergistic against Microsporum species, while amphotericin
B acted synergistically against T. rubrum in combination
with pravastatin. Similarly, nystatin-simvastatin combina-
tion was synergistic against Microsporum species but nys-
tatin acted synergistically in combination with rosuvastatin
against only M. gypseum. Since griseofulvin caused com-
plete growth inhibition of dermatophytes at low concen-
tration (0.125–1μg/ml), improved results could not be ex-
pected in combination with statins. The only exception was
the synergistic interactions againstM. gypseum when grise-
ofulvin was combined with simvastatin and fluvastatin. The
interactions were mostly indifferent between primycin and
statins, the only synergistic interaction was detected be-
tween primycin and simvastatin at T. rubrum.
Although synergistic interactions were observed with
every investigated strain, the majority were found with
T. rubrum and M. gypseum. While each statin could form
synergistic interactions with antifungals, the most frequent
interactions were observed with simvastatin. Dermatophyte
fungi were completely insensitive to pravastatin, even so its
combination with amphotericin B was synergistic against
T. rubrum, and its combination with itraconazole was syn-
ergistic against M. canis.
Discussion
Antifungal activities of statins against dermatophytes has
not been previously demonstrated in vitro but the evalu-
ation of the data from the present investigations clearly
suggest that these fungi are susceptible to these drugs. This
may be a class effect of statins as antimicrobial activity has
been demonstrated for fluvastatin, atorvastatin, rosuvas-
tatin, lovastatin and simvastatin, a collection of synthetic
and fungal derived drugs. However, pravastatin was found
to be completely ineffective in this and previous studies. At
the same time, pravastatin displayed antifungal activity in
vitro against C. albicanswhen YM broth rather than RPMI
was used as the test medium [32].
Since we used the M38-A2 in vitro test protocol of the
CLSI, RPMI 1640 was employed in our investigations [26].
However, some modifications were made as for example
the microtiter plates were incubated at 30◦C instead of the
recommended 35◦C. Since the MIC values were the same
at both temperatures, we selected 30◦C as it is the optimal
growth temperature of the slower growing dermatophyte
fungi [28,33]. The inoculumwas also slightly different since
we used microconidia without any hyphal elements pre-
pared using the modified method of Santos et al. [28]. The
growth of fungi from microconidial inocula was homoge-
neous which allowed for easier interpretation of results and
improved reproducibility of the tests.
In our study, substantial differences were observed
among statins relative to their antifungal properties with
fluvastatin and simvastatin were the most effective, fol-
lowed by lovastatin, rosuvastatin, atorvastatin and pravas-
tatin. A similar phenomenon was demonstrated in our pre-
vious work where the antifungal effects of statins were in-
vestigated in vitro against different yeasts and filamentous
fungi [16]. In these tests, fluvastatin and simvastatin both
displayed the strongest antifungal activity but, atorvastatin
and rosuvastatin were found to be more effective than lo-
vastatin. In other studies, statins also acted differently on
the growth of fungi, their antifungal effects against different
yeast, ascomycetes and zygomycetes have been comprehen-
sively reviewed [34].
Ergosterol is an essential component of the fungal
plasma membranes, and the inhibition of its synthesis neg-
atively influences the membrane fluidity [9]. The antifungal
effect of statins are due in part to their role on ergosterol
levels, as well as to their indirect effect on cell signaling,
proliferation and differentiation through inhibition of the
synthesis of important terpenoids [35,36].
The antifungal activity of statins cannot be exploited
in current clinical practice as the high concentrations re-
quired to achieve a reliable antimicrobial effect are well
above the maximum achievable serum levels in humans
[37,38]. At the same time, they should be promising
agents in combination therapy as they can act synergisti-
cally with a number of clinically used antifungal agents,
allowing substantial decreases in the latter therapeutic
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concentrations [11,12,14–19]. Treatment of dermatophyte
infection generally involves oral and/or topical formulations
of the two main antifungal drug families, the azoles and
the allylamines, particularly itraconazole and terbinafine
[39]. Griseofulvin is also in use up to this day, mainly
for the treatment of pediatric patients [24]. The intro-
duction of new therapeutic agents is rare and restricted
to those with a wide-action spectrum, topical agents with
anti-inflammatory as well as antifungal actions, and use of
combination of existing oral/topical antifungal agents [39].
In our study, the presently employed antifungals were com-
binedwith the lipid-lowering statins, and the numerous syn-
ergistic interactions noted during the study demonstrated
that statins that were originally non-antifungal might be of
use in combination therapy. In some cases, statins may act
synergistically with antifungal drugs even if the statins are
ineffective when they used alone [11,12]. The same phe-
nomenon was observed in our study of the use of ator-
vastatin and pravastatin. Atorvastatin inhibited the growth
of the investigated dermatophyte fungi only at the high-
est applied concentration, but it showed significant an-
tifungal activity in combination with itraconazole, keto-
conazole, fluconazole or terbinafine. The administration of
statins together with azole antifungals that are predomi-
nantlymetabolized by the same cytochrome P450 enzyme in
the liver (CYP3A4) is substantially limited, because azoles
reduce the metabolic clearance of statins, hereby the in-
creased concentration of the co-administered statins in the
serum may cause severe side-effects in the patients, such as
myositis and rhabdomyolysis [37,40,41]. Griseofulvin co-
administration with atorvastatin, and likely the whole class
of similar drugs should be avoided [24]. These drug interac-
tions could limit their systemic administration, but it should
be noted that fluvastatin and pravastatin have a lower po-
tential than other statins for such interactions. Fluvastatin
is predominantly metabolized by the CYP2C9 isoenzyme,
whereas pravastatin is excreted by the renal mechanism and
does not undergo significantmetabolism via the cytochrome
P450 system [42,43]. Other statin-azole combinations may
be applicable as topical therapy for dermatophyte infec-
tions, as serum absorption are supposed to be negligible
with topical dermatophytosis therapy causing onlymild and
transient skin reactions at the application site [39].
In the present study, we detected synergistic interactions
between statins and antifungal agents in many cases. The
application of these combinations in the clinical practice
for the prevention or treatment fungal infections require
further studies, including in vivo animal experiments and
prospective controlled trials in at-risk human populations,
which can evaluate the practical efficiency of the statin-
antifungals combinations.
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